Alterity Therapeutics H1 2026 Earnings Report

Alterity Therapeutics EPS Results

• Actual EPS: -$0.18
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Alterity Therapeutics Revenue Results

• Actual Revenue: $0.93 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Alterity Therapeutics Announcement Details

• Quarter: H1 2026
• Date: 1/31/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Alterity Therapeutics (NASDAQ:ATHE) is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials. Another key program, PBT434, is an oral small molecule aimed at modulating metal-mediated oxidative stress, currently in early-stage development for Parkinson’s disease and related disorders.

Originally established in 1998 as Neuren Pharmaceuticals, the company rebranded to Alterity Therapeutics in 2023 to reflect its distinct focus on neurodegenerative conditions. Headquartered in Australia, Alterity conducts global clinical studies across North America, Europe and Australia, leveraging strategic partnerships to advance its pipeline toward regulatory milestones.